Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

Context  Recent case reports detail the successful use of temozolomide in the management of aggressive pituitary tumours. O6‐methylguanine‐DNA methyltransferase (MGMT) is a DNA repair protein that counteracts the effect of temozolomide.

[1]  C. Manstein.  Malignant , 1995, Definitions.

[2]  A. Falini,et al.  Tumours , 2008, Neurological Sciences.

[3]  B. O'neill,et al.  MGMT Immunohistochemical Expression and Promoter Methylation in Human Glioblastoma , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[4]  R. McLendon,et al.  MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy , 2008, Acta Neuropathologica.

[5]  K. Hoang-Xuan,et al.  Molecular genetic markers as predictors of response to chemotherapy in gliomas , 2007, Current opinion in oncology.

[6]  Shuji Ogino,et al.  MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. , 2007, Carcinogenesis.

[7]  H. Arai,et al.  Effectiveness of interferon-beta and temozolomide combination therapy against temozolomide-refractory recurrent anaplastic astrocytoma , 2007, World journal of surgical oncology.

[8]  D. Hunter,et al.  Genetic association and functional studies of major polymorphic variants of MGMT. , 2007, DNA repair.

[9]  L. Vlahos,et al.  Phase II Study of Temozolomide and Concomitant Whole-Brain Radiotherapy in Patients with Brain Metastases from Solid Tumors , 2007, Oncology Research and Treatment.

[10]  B. Skogseid,et al.  Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors , 2007, Clinical Cancer Research.

[11]  Pierre-Marie Martin,et al.  Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. A. Futreal,et al.  Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.

[13]  A. Tischler,et al.  Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists , 2007, Pituitary.

[14]  K. Kovacs,et al.  Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. , 2007, Human pathology.

[15]  K. Hoang-Xuan,et al.  MGMT methylation: A marker of response to temozolomide in low‐grade gliomas , 2006, Annals of neurology.

[16]  A. Beckers,et al.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.

[17]  C. Eskey,et al.  Long-term response of pituitary carcinoma to temozolomide. Report of two cases. , 2006, Journal of neurosurgery.

[18]  K. Kovacs,et al.  Antitumour effects of temozolomide in a man with a large, invasive prolactin‐producing pituitary neoplasm , 2006, Clinical endocrinology.

[19]  A. Gill,et al.  Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias , 2006, The American journal of surgical pathology.

[20]  K. Aldape,et al.  Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms , 2006, Clinical Cancer Research.

[21]  H. Shahinian,et al.  Temozolomide: a novel treatment for pituitary carcinoma. , 2006, The Lancet. Oncology.

[22]  T. Naoe,et al.  Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression Is a Favorable Prognostic Marker in Diffuse Large B-Cell Lymphoma , 2006, International journal of hematology.

[23]  J. Rey,et al.  Promoter CpG methylation of multiple genes in pituitary adenomas: frequent involvement of caspase-8. , 2006, Oncology reports.

[24]  Lili Liu,et al.  Targeted Modulation of MGMT: Clinical Implications , 2006, Clinical Cancer Research.

[25]  K. Fujii,et al.  Down-regulation of O6-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. , 2005, Oncology reports.

[26]  A. Rowan,et al.  O6-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions , 2005, Gut.

[27]  M. Buchfelder,et al.  Diagnosis and Management of Pituitary Carcinomas , 2005 .

[28]  H. Soejima,et al.  Tumor Progression Through Epigenetic Gene Silencing of O6−Methylguanine-DNA Methyltransferase in Human Biliary Tract Cancers , 2005, Annals of Surgical Oncology.

[29]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[30]  M. Wolter,et al.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors , 2005, International journal of cancer.

[31]  M. Buchfelder,et al.  Clinical review: Diagnosis and management of pituitary carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[32]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[33]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[34]  H. Meijers-Heijboer,et al.  Microsatellite Instability, Immunohistochemistry, and Additional PMS2 Staining in Suspected Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[35]  A. Grossman,et al.  Malignant Pituitary Tumours , 1998, Pituitary.

[36]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[37]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[38]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[39]  J. J. Mukherjee,et al.  The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. , 1998, The Journal of clinical endocrinology and metabolism.

[40]  R. Thakker,et al.  Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. , 1997, The Journal of clinical endocrinology and metabolism.

[41]  Lalitha Krishnan,et al.  Somatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma , 1996, Clinical endocrinology.

[42]  J. Costello,et al.  Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. , 1994, The Journal of biological chemistry.